Dr Enrique Gallardo speaks to ecancer about final overall survival results from the EORTC 1333/PEACE-3 trial.

He discusses the trial results which showed that combining enzalutamide with radium-223 significantly prolongs overall survival in men with bone-dominant metastatic castration-resistant prostate cancer.

The combination also improves radiological progression-free survival, with a safety profile similar to enzalutamide alone.

Dr Gallardo breaks down how this therapy works, the key outcomes, and what it means for patients with advanced prostate cancer.